Author

Hussein Sultan

WUSTL - Cited by 321 - Tumor Immunology - Cancer vaccines

Biography

Dr. Hussein Sultan is an Assistant Professor in the Department of Physical Medicine, Rheumatology and Rehabilitation, Alexandria University, Alexandria, Egypt. His research interest includes Physical Medicine, Hearing Science, etc. He has published more than 10 publications and the articles are informative and got good citations.
Title
Cited by
Year
Optimization of peptide vaccines to induce robust antitumor CD4 T-cell responses
T Kumai, S Lee, HI Cho, H Sultan, H Kobayashi, Y Harabuchi, E CelisCancer immunology research 5 (1), 72-83, 2017201
62
2017
Designing therapeutic cancer vaccines by mimicking viral infections
H Sultan, VI Fesenkova, D Addis, AE Fan, T Kumai, J Wu, AM Salazar, ...Cancer Immunology, Immunotherapy 66, 203-213, 2017201
45
2017
Poly-ICLC, a multi-functional immune modulator for treating cancer
H Sultan, AM Salazar, E CelisSeminars in Immunology 49, 101414, 2020202
39
2020
The route of administration dictates the immunogenicity of peptide-based cancer vaccines in mice
H Sultan, T Kumai, T Nagato, J Wu, AM Salazar, E CelisCancer Immunology, Immunotherapy 68, 455-466, 2019201
34
2019
Poly-IC enhances the effectiveness of cancer immunotherapy by promoting T cell tumor infiltration
H Sultan, J Wu, VI Fesenkova, AE Fan, D Addis, AM Salazar, E CelisJournal for immunotherapy of cancer 8 (2), 2020202
33
2020
Role of dendritic cell-mediated immune response in oral homeostasis: A new mechanism of osteonecrosis of the jaw
R Elsayed, Z Kurago, CW Cutler, R Arce, J Gerber, E Celis, H Sultan, ...FASEB journal: official publication of the Federation of American Societies …, 2020202
25
2020
Role of MDA5 and interferon-I in dendritic cells for T cell expansion by anti-tumor peptide vaccines in mice
H Sultan, J Wu, T Kumai, AM Salazar, E CelisCancer Immunology, Immunotherapy 67, 1091-1103, 2018201
19
2018
Effective antitumor peptide vaccines can induce severe autoimmune pathology
H Sultan, J Trillo-Tinoco, P Rodriguez, E CelisOncotarget 8 (41), 70317, 2017201
15
2017
Sustained persistence of IL2 signaling enhances the antitumor effect of peptide vaccines through T-cell expansion and preventing PD-1 inhibition
H Sultan, T Kumai, VI Fesenkova, AE Fan, J Wu, HI Cho, H Kobayashi, ...Cancer immunology research 6 (5), 617-627, 2018201
12
2018
31st annual meeting and associated programs of the society for immunotherapy of cancer (Sitc 2016): Part two: National harbor, md, USA. 9-13 November 2016
C Ager, M Reilley, C Nicholas, T Bartkowiak, A Jaiswal, M Curran, ...Journal for ImmunoTherapy of Cancer 4, 7-221, 2016201
10
2016
The effect of α1-antitrypsin deficiency combined with increased bacterial loads on chronic obstructive pulmonary disease pharmacotherapy: a prospective, parallel, controlled …
MG Hennawy, NM Elhosseiny, H Sultan, W Abdelfattah, Y Akl, NA Sabry, ...Journal of Advanced Research 7 (6), 1019-1028, 2016201
4
2016
1092 The CD8+ T cell selectivity of AB248 is essential for optimal anti-tumor activity and safety in nonclinical models
109 The CD8+ T cell selectivity of AB48 is essential for optimal anti-tumor activity and safety in nonclinical modelsK Moynihan, D Pappas, H Sultan, T Park, M Kumar, R Lan, I Ni, J Chen, ...Journal for ImmunoTherapy of Cancer 10 (Suppl ), 0
2
2022
578 CD8-targeted IL-2 drives potent anti-tumor efficacy and promotes action of tumor specific vaccines
578 CD8-targeted IL- drives potent anti-tumor efficacy and promotes action of tumor specific vaccinesH Sultan, K Moynihan, Y Song, S Ameh, T Schumacher, YA Yeung, ...Journal for ImmunoTherapy of Cancer 9 (Suppl ), A607-A607, 010
2
2021
1083 AB821 is a CD8+ T cell selective IL-21 with enhanced bioavailability that mediates potent anti-tumor activity, cytotoxicity, and expansion of memory CD8+ T cells
083 AB82 is a CD8+ T cell selective IL-2 with enhanced bioavailability that mediates potent anti-tumor activity, cytotoxicity, and expansion of memory CD8+ T cellsR Greer, H Nguyen, P Mesko, R Lan, WW Prior, H Sultan, M Sukthankar, ...Journal for ImmunoTherapy of Cancer 0 (Suppl 2), 2022202
1
2022